Vise Technologies Inc. Invests $518,000 in Natera, Inc. $NTRA

Vise Technologies Inc. acquired a new stake in Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,909 shares of the medical research company’s stock, valued at approximately $518,000.

Several other large investors have also added to or reduced their stakes in the business. Trust Co. of Vermont acquired a new stake in Natera in the 2nd quarter valued at $26,000. Reflection Asset Management acquired a new position in shares of Natera during the 4th quarter worth about $29,000. Elevation Wealth Partners LLC acquired a new position in shares of Natera during the 2nd quarter worth about $30,000. Palladiem LLC bought a new position in shares of Natera in the 4th quarter valued at about $31,000. Finally, Horizon Investments LLC bought a new position in shares of Natera in the 3rd quarter valued at about $32,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the transaction, the insider owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Gail Boxer Marcus sold 11,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the transaction, the director owned 6,183 shares in the company, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 177,955 shares of company stock worth $40,704,193. 5.05% of the stock is currently owned by insiders.

Natera Trading Down 1.3%

NTRA opened at $327.72 on Tuesday. The stock’s fifty day simple moving average is $276.45 and its 200 day simple moving average is $230.09. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $333.56. The stock has a market cap of $47.24 billion, a PE ratio of -240.97 and a beta of 1.51.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.74) earnings per share. Equities analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Robert W. Baird set a $348.00 target price on Natera in a report on Friday, August 7th. Guggenheim raised their price target on Natera from $290.00 to $360.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Barclays reissued an “overweight” rating and issued a $340.00 price objective on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $319.38.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.